REFERENCES

1. Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Kissling W, et al. Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons. Schizophr Bull 2010 May 31 [Epub ahead of print].
2. Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Lobos CA, et al. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Bull 2010;123(2-3):225-233.
3. Buckley PF, Stahl SM. Pharmacological treatment of negative symptoms of schizophrenia: therapeutic opportunity or cul-de-sac? Acta Psychiatr Scand 2007;115(2):93-100.
4. DePaulo JR Jr. Bipolar disorder treatment: an evidence-based reality check (editorial). Am J Psychiatry 2006;163(2):175-176.
5. Fan X, Pristach C, Liu EY, Freudenreich O, Henderson DC, Goff DC. Elevated serum levels of C-reactive protein are associated with more severe psychopathology in a subgroup of patients with schizophrenia. Psychiatry Res 2007;149(1-3):267-271.
6. Dickerson F, Stallings C, Origoni A, Boronow J, Yolken R. C-reactive protein is associated with the severity of cognitive impairment but not of psychiatric symptoms in individuals with schizophrenia. Schizophr Res 2007;93:261-265.
7. Suvisaari J, Loo B-M, Saarni SE, Perala J, Saarni S, Jula A. Inflammation in psychotic disorders: a population-based study (abstract). Schizophr Res 2010;117:488.
8. Saetre P, Emilsson L, Axelsson E, Kreuger J, Lindholm E, Jazin E. Inflammation-related genes up-regulated in schizophrenia brains. BMC Psychiatry 2007;7:46.
9. Diaz FJ, Pérez-Iglesias R, Mata I, Martínez-Garcia O, Vázquez-Barquero JL, de Leon J, et al. Possible effects of some antipsychotic drugs on C-reactive protein in a drug-naïve psychotic sample. Schizophr Res 2010;121(1-3):207-212.
10. Laan W, Grobbee DE, Selten J-P, Heijnen CJ, Kahn RS, Burger H. Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2010;71(5):520-527.
11. Dickerson F, Stallings C, Origoni A, Boronow J, Yolken R. Elevated serum levels of C-reactive protein are associated with mania symptoms in outpatients with bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 2007;31(4):952-955.
12. Goldstein BI, Kemp DE, Soczynska JK, McIntyre RS. Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature. J Clin Psychiatry 2009;70(8):1078-1090.
13. Basselin M, Kim H-W, Chen M, Ma K, Rapoport SI, Murphy RC, et al. Lithium modifies brain arachidonic and docosahexaenoic metabolism in rat lipopolysaccharide model of neuroinflammation. J Lipid Res 2010;51(5):1049-1056.
14. Müller N, Riedel M, Scheppach C, Brandstätter B, Sokullu S, Krampe K, et al. Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am J Psychiatry 2002;159(6):1029-1034.
15. Müller NE, Riedel M, Dehning S, Spellmann I, Mueller-Arends A, Cerovecki A, et al. Is the therapeutic effect of celecoxib in schizophrenia depending from duration of disease? (abstract). Neuropsychopharmacology 2004;29(Suppl 1):S176.
16. Rapaport MH, Delrahim KK, Bresee CJ, Maddux RE, Ahmadpour O, Dolnak D. Celecoxib augmentation of continuously ill patients with schizophrenia. Biol Psychiatry 2005;57(12):1594-1596.
17. Akhondzadeh S, Tabatabaee M, Amini H, Ahmadi Abhari SA, Abbasi SH, Behnam B. Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial. Schizophr Res 2007;90(1-3):179-185.
18. Muller N, Krause D, Dehning S, Musil R, Schennach-Wolff R, Obermeier M, et al. Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment. Schizophr Res 2010;121(1-3):118-124.
19. Nery FG, Monkul ES, Hatch JP, Fonseca M, Zunta-Soares GB, Frey BN, et al. Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a double-blind, randomized, placebo-controlled study. Hum Psychopharmacol Clin Exp 2008;23(2):87-94.
20. Littleton-Kearney MT, Ostrowski NL, Cox DA, Rossberg MI, Hurn PD. Selective estrogen receptor modulators: tissue actions and potential for CNS protection. CNS Drug Rev 2002;8(3):309-330.
21. Bergemann N, Abu-Tair F, Strowitzki T. Estrogen in the treatment of late-onset schizophrenia (letter). J Clin Psychopharmacol 2007;27(6):718-720.
22. Kulkarni J, de Castella A, Smith D, Taffe J, Keks N, Copolov D. A clinical trial of the effects of estrogen in acutely psychotic women. Schizophr Res 1996;20(3):247-252.
23. Kulkarni J, Riedel A, de Castella AR, Fitzgerald PB, Rolfe TJ, Taffe J, et al. Estrogen—a potential treatment for schizophrenia. Schizophr Res 2001;48(1):137-144.
24. Kulkarni J, de Castella A, Fitzgerald PB, Gurvich CT, Bailey M, Bartholomeusz C, et al. Estrogen in severe mental illness. Arch Gen Psychiatry 2008;65(8):955-960.
25. Akhondzadeh S, Nejatisafa AA, Amini H, Mohammadi MR, Larijani B, Kashani L, et al. Adjunctive estrogen treatment in women with chronic schizophrenia: a double-blind, randomized, and placebo-controlled trial. Prog Neuropsychopharmacol Biol Psychiatry 2003;27(6):1007-1012.
26. Behdani F, Hebrani P, Mohamad Nejad M. Adjunctive estrogen treatment in women with chronic schizophrenia admitted in Hejazi and Ibn-e-Sina (abstract). Eur Neuropsychopharmacol 2008;18(Suppl):S390.
27. Bergemann N, Mundt C, Parzer P, Pakrasi M, Eckstein-Mannsperger U, Haisch S, et al. Estrogen as an adjuvant therapy to antipsychotics does not prevent relapse in women suffering from schizophrenia: results of a placebo-controlled double-blind study. Schizophr Res 2005;74(2-3):125-134.
28. Lindamer LA, Buse DC, Lohr JB, Jeste DV. Hormone replacement therapy in postmenopausal women with schizophrenia: positive effect on negative symptoms? Biol Psychiatry 2001;49:47-51.
29. Lousã MR, Marques AP, Elkis H, Bassitt D, Diegoli M, Gattaz WF. Conjugated estrogens as adjuvant therapy in the treatment of acute schizophrenia: a double-blind study. Schizophr Res 2004;66(2-3):97-100.
30. Kulkarni J, de Castella A, Headey B, Marston N, Sinclair K, Lee S, et al. Estrogens and men with schizophrenia: is there a case for adjunctive therapy? Schizophr Res 2011;125(2-3):278-283.
31. Kulkarni J, Gurvich C, Lee SJ, Gilbert H, Gavrilidis E, de Castella A, et al. Piloting the effective therapeutic dose of adjunctive selective estrogen receptor modulator treatment in postmenopausal women with schizophrenia. Psychoneuroendocrinology 2010;35(8):1142-1147.
32. Usall J, Huerta-Ramos E, Iniesta R, Cobo J, Araya S, Roca M, et al. Raloxifene as an adjunctive treatment for postmenopausal women with schizophrenia: a double-blind, randomized, placebo-controlled trial. J Clin Psychiatry 2011 Aug 23 [Epub ahead of print].
33. Chouinard G, Steinberg S, Stein W. Estrogen-Progesterone combination: another mood stabilizer? (letter). Am J Psychiatry 1987;144(6):826.
34. Goff DC, Bottiglieri T, Arning E, Shih V, Freudenreich O, Evins AE, et al. Folate, homocysteine, and negative symptoms in schizophrenia. Am J Psychiatry 2004;161(9):1705-1708.
35. Godfrey PSA, Toone BK, Carney MWP, Flynn TG, Bottiglieri T, Laundy M, et al. Enhancement of recovery from psychiatric illness by methylfolate. Lancet 1990;336(8712):392-395.
36. Levine J, Stahl Z, Sela B-A, Ruderman V, Shumaico O, Babushkin I, et al. Homocysteine-reducing strategies improve symptoms in chronic schizophrenic patients with hyperhomocysteinemia. Biol Psychiatry 2006;60:265-269.
37. Hill M, Shannahan K, Jasinski S, Macklin EA, Raeke L, Roffman JL, et al. Folate supplementation in schizophrenia: a possible role for MTHFR genotype. Schizophr Res 2011; Feb 18 [Epub ahead of print].
38. Dittmann S, Seemüller F, Grunze HC, Schwarz MJ, Zach J, Fast K, et al. The impact of homocysteine levels on cognition in euthymic bipolar patients: a cross-sectional study. J Clin Psychiatry 2008;69(6):899-906.
39. Yong VW, Wells J, Giuliani F, Casha S, Power C, Metz LM. The promise of minocycline in neurology. Lancet Neurol 2004;3(12):744-751.
40. Zhang L, Shirayama Y, Ioy M, Hashimoto K. Minocycline attenuates hyperlocomotion and prepulse inhibition deficits in mice after administration of the NMDA receptor agonist dizoclipine. Neuropsychopharmacology 2007;32(9):2004-2010.
41. Levkovitz Y, Levi U, Braw Y, Cohen H. Minocycline, a second-generation tetracycline, as a neuroprotective agent in animal model of schizophrenia. Brain Res 2007;1154:154-162.
42. Miyaoka T, Yasukawa R, Yasuda H, Hayashida M, Inagaki T, Horiguchi J. Possible antipsychotic effects of minocycline in patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2007;31(1):304-307.
43. Chaves C, Marque CR, Chaudhry IB, Husain N, Minhas F, Oliveira JP, et al. Short-term improvement by minocycline added to olanzapine antipsychotic treatment in paranoid schizophrenia (abstract). Schizophr Bull 2009;35:354.
44. Miyaoka T. Clinical potential of minocycline for schizophrenia. CNS Neurol Disord 2008;7(4):376-381.
45. Miyaoka T, Yasukawa R, Yasuda H, Hayashida M, Inagaki T, Horiguchi J. Minocycline as adjunctive therapy for schizophrenia: an open-label study. Clin Neuropharmacology 2008;31(5):287-292.
46. Chaudhry IB, Husain N, Hallak J, Minhas FA, Dursun S, Richardson P, et al. Preventing clinical deterioration in first episode psychosis: potential role of minocycline in neuroprotection (abstract). Biol Psychiatry 2009;64:915.
47. Levkovitz Y, Mendlovich S, Riwkes S, Braw Y, Levkovitch-Verbin H, Gal G, et al. A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J Clin Psychiatry 2010;71(2):138-149.
48. Levine J, Cholestoy A, Zimmerman J. Possible antidepressant effect of minocycline (letter). Am J Psychiatry 1996;153(4):582.
49. Berk M, Ichim C, Brook S. Efficacy of mirtazapine add on therapy to haloperidol in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study. Int Clin Psychopharmacol 2001;16(2):87-92.
50. Zoccali R, Muscatello MR, Cedro C, Neri P, La Torre D, Spina E, et al. The effect of mirtazapine augmentation of clozapine in the treatment of negative symptoms of schizophrenia: double-blind, placebo-controlled study. Int Clin Psychopharmacol 2004;19(2):71-76.
51. Joffe G, Terevnikov V, Joffe M, Stenberg J-H, Burkin M, Tiihonen J. Add-on mirtazapine enhances antipsychotic effect of first generation antipsychotics in schizophrenia: a double-blind, randomized, placebo-controlled trial. Schizophr Res 2009;108(1-3):245-251.
52. Abbasi S-H, Behpournia H, Ghoreshi A, Salehi B, Raznahan M, Rezazadeh S-A, et al., The effect of mirtazapine add on therapy to risperidone in the treatment of schizophrenia: a double-blind randomized placebo-controlled trial. Schizophr Res 2010;116(2-3):101-106.
53. Berk M, Gama CS, Sundram S, Hustig H, Koopowitz L, D’Souza R, et al. Mirtazapine add-on therapy in the treatment of schizophrenia with atypical antipsyotics: a double-blind, randomized, placebo-controlled clinical trial. Hum Psychopharmacol 2009;24(3):233-238.
54. Hieber R, Dellenbaugh T, Nelson LA. Role of mirtazapine in the treatment of antipsychoic-induced akathisia. Ann Pharmacother 2008;42(6):841- 846.
55. Poyurovsky M, Pashinian A, Weizman R, Fuchs C, Weizman A. Low-dose mirtazapine: a new option in the treatment of antipsychotic-induced akathisia: a randomized, double-blind, placebo- and propranolol-controlled trial. Biol Psychiatry 2006;59(11):1071-1077.
56. Poyurovsky M, Epshtein S, Fuchs C, Schneidman M, Weizman R, Weizman A. Efficacy of low-dose mirtazapine in neuroleptic-induced akathisia: a double-blind randomized placebo-controlled pilot study. J Clin Psychopharmacol 2003;23(3):305-308.
57. Goyal N, Sinha VK. Mirtazapine-induced manic switch in adolescent unipolar depression (letter). Aust N Z J Psychiatry 2008;42(12):1070-1071.
58. Horrobin DF, Glen AIM, Vaddadi K. The membrane hypothesis of schizophrenia. Schizophr Res 1994;13(3):195-207.
59. Freeman MP, Hibbeln JR, Wisner KL, Davis JM, Mischoulon D, Peet M, et al. Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry. J Clin Psychiatry 2006;67(12):1954-1967.
60. Kinney DK, Teixeira P, Hsu D, Napoleon SC, Crowley DJ, Miller A, et al. Relation of schizophrenia prevalence to latitude, climate, fish consumption, infant mortality, and skin color: a role for prenatal vitamin D deficiency and infections? Schizophr Bull 2009;35(3):582-595.
61. Harper KN, Hibbeln JR, Deckelbaum R, Quesenberry CP Jr, Schaefer CA, Brown AS. Maternal serum docosahexaenoic acid and schizophrenia spectrum disorders in adult offspring. Schizophr Res 2011;128(1-3):30-36.
62. Fenton WS, Hibbeln J, Knable M. Essential fatty acids, lipid membrane abnormalities, and the diagnosis and treatment of schizophrenia. Biol Psychiatry 2000;47(1):8-21.
63. Evans DR, Parikh VV, Khan MM, Coussons C, Buckley PF, Mahadik SP. Red blood cell membrane essential fatty acid metabolism in early psychotic patients following antipsychotic drug treatment. Prostaglandins Leukot Essent Fatty Acids 2003;69(6):393-399.
64. Fenton WS, Dickerson F, Boronow J, Hibbeln JR, Knable M. A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia. Am J Psychiatry 2001;158(12):2071-2074.
65. Peet M, Horrobin DF. A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms. J Psychiatr Res 2002;36(1):7-18.block
66. Berger GE, Proffitt T-M, McConchie M, Yuen H, Wood SJ, Amminger GP, et al. Ethyl-eicosapentaenoic acid in first-episode psychosis: a randomized, placebo-controlled trial. J Clin Psychiatry 2007;68(12):1867-1875.
67. Peet M, Brind J, Ramchand CN, Shah S, Vankar GK. Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia. Schizophr Res 2001;49(3):243-251.
68. Emsley R, Myburgh C, Oosthuizen P, van Rensburg SJ. Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia. Am J Psychiatry 2002;159(9):1596-1598.
69. Amminger GP, Schäfer MR, Papageorgiou K, Kleir CM, Cotton SM, Harrigan SM, et al. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch Gen Psychiatry 2010;67(2):146-154.
70. Stoll AL, Severus WE, Freeman MP, Rueter S, Zboyan HA, Diamond E, et al. Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial. Arch Gen Psychiatry 1999;56(5):407-412.
71. Frangou S, Lewis M, McCrone P. Efficacy of ethyl-eicosapentaenoic acid in bipolar depression: randomized double-blind placebo-controlled study. Br J Psychiatry 2006;188:46-50.
72. Keck PE, Mintz J, McElroy SL, Freeman MP, Suppes T, Frye MA, et al. Double-blind, randomized, placebo-controlled trials of ethyl-eicosapentanoate in the treatment of bipolar depression and rapid cycling bipolar disorder. Biol Psychiatry 2006;60(9):1020-1022.
73. Osher Y, Bersudsky Y, Belmaker RH. Omega-3 eicosapentaenoic acid in bipolar depression: report of a small open-label study. J Clin Psychiatry 2005;66(6):726-729.
74. Clayton EH, Hanstock TL, Hirneth SJ, Kable CJ, Garg ML, Hazell PL. Reduced mania and depression in juvenile bipolar disorder associated with long-chain omega-3 polyunsaturated fatty acid supplementation. Eur J Clin Nutr 2009;63(8):1037-1040.
75. Irving CB, Mumby-Croft R, Joy LA. Polyunsaturated fatty acid supplementation for schizophrenia (review). The Cochrane Collaboration. John Wiley and Sons, 2010, pp. 1-64.
76. Lin P-Y, Su K-P. A meta-analytic review of double-blind, placebo-controlled trials of antidepressant efficacy of omega-3 fatty acids. J Clin Psychiatry 2007;68(7):1056-1061.
77. Benkert O, Müller-Siecheneder F, Wetzel H. Dopamine agonists in schizophrenia: a review. Eur Neuropsychopharmacol 1995;5(Suppl):43-53.
78. Kasper S, Barnas C, Heiden A, Volz HP, Laakmann G, Zeit H, et al. Pramipexole as adjunct to haloperidol in schizophrenia: safety and efficacy. Eur Neuropsychopharmacol 1997;7(1):65-70.
79. Kelleher JP, Centorrino F, Huxley NA, Hennen J, Eakin M, Kidwell J, et al. Pilot, randomized controlled trial of pramipexole to augment antipsychotic treatment. Eur Neuropsychopharmacol, in press.
80. Goldberg JF, Burdick KE, Endick CJ. Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. Am J Psychiatry 2004;161(3):564-566.
81. Zarate CA Jr, Payne JL, Singh J, Quiroz JA, Luckenbaugh DA, Denicoff KD, et al. Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. Biol Psychiatry 2004;56(1):54-60.
82. Malhotra AK, Braga RJ, Nnadi C, Shaya Y, Stearns WH, Burdick KE. Cognitive enhancement in euthymic bipolar I patients with pramipexole: a placebo-controlled adjunctive trial (poster). Presented at the 49th annual meeting of the American College of Neuropsychopharmacology, Miami, Fla., December 5-9, 2010.
83. Lettanzi L, Dell’Osso L, Cassano P, Pini S, Rucci P, Houck PR, et al. Pramipexole in treatment-resistant depression: a 16-week naturalistic study. Bipolar Disord 2002;4(5):307-314.
84. Perugi G, Toni C, Ruffolo G, Frare F, Akiskal H. Adjunctive dopamine agonists in treatment-resistant bipolar II depression: an open case series. Pharmacopsychiatry 2001;34(4):137-141.
85. Sporn J, Ghaemi SN, Sambur MR, Rankin MA, Recht J, Sachs GS, et al. Pramipexole augmentation in the treatment of unipolar and bipolar depression: a retrospective chart review. Ann Clin Psychiatry 2000;12(3):137-140.
86. Corrigan MH, Denahan AQ, Wright CE, Ragual RJ, Evans DL. Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depress Anxiety 2000;11(2):58-65.
87. Aiken CB. Pramipexole in psychiatry: a systematic review of the literature. J Clin Psychiatry 2007;68(8):1230-1236.
88. Savitz AJ. Multi-year continuation study of pregnenolone in patients with schizophrenia (abstract). Biol Psychiatry 2010;67:22S.
89. Marx CE, Keefe RSE, Buchanan RW, Hamer RM, Kilts JD, Bradford DW, et al. Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia. Neuropsychopharmacology 2009;34(8):1885-1903.
90. Ritsner MS, Gibel A, Shleifer T, Boguslavsky I, Zayed A, Maayan R, et al. Pregnenolone and dehydroepiandrosterone as an adjunctive treatment in schizophrenia and schizoaffective disorder: an 8-week, double-blind, randomized, controlled, 2-center, parallel-group trial. J Clin Psychiatry 2010;71(10):1351-1362.
91. Osuji IJ, Vera-Bolaños E, Carmody TJ, Brown ES. Pregnenolone for cognition and mood in dual diagnosis patients. Psychiatry Res 2010;178(2):309-312.
92. From Discovery to Cure: Accelerating the Development of New and Personalized Interventions for Mental Illnesses, Report of the National Advisory Mental Health Council’s Workgroup, August 2010, www.nimh.nih.gov/about/advisory-boards-and-groups/namhc/reports/fromdiscoverytocure.pdf, last accessed on March 8, 2011.
93. Wazana A. Physicians and the pharmaceutical industry: is a gift ever just a gift? JAMA 2000;283(3):373-380.
94. Blumenthal D. Doctors and drug companies. N Engl J Med 2004;351(18):1885-1890.
95. Brodkey A. The role of the pharmaceutical industry in teaching psychopharmacology: a growing problem. Acad Psychiatry 2005;29(2):222-229.
96. Prosser H, Almond S, Walley T. Influences on GPs’ decision to prescribe new drugs—the importance of who says what. Fam Pract 2003;20(1):61-68.